CABA

Cabaletta Bio, Inc. (CABA) - 2025 Annual Report Summary

Business Context and Reporting Period

Cabaletta Bio, Inc. is a late clinical-stage biotechnology company developing engineered T cell therapies (CAR T) for autoimmune diseases. The company's lead product candidate, rese-cel (resecabtagene autoleucel), utilizes the proprietary CABA platform to deplete B cells and potentially "reset" the immune system. The reporting period covers the fiscal year ended December 31, 2025.

The company is advancing Phase 1/2 trials across five indications: myositis, systemic lupus erythematosus (SLE), systemic sclerosis (SSc), generalized myasthenia gravis (gMG), and pemphigus vulgaris (PV). In December 2025, Cabaletta initiated a registrational cohort for myositis (dermatomyositis/anti-synthetase syndrome).

Key Financial Metrics

Note: The filing text does not provide specific gross margin or operating margin percentages as the company has no revenue.

Material Changes vs. Prior Period

• Increased Burn Rate: Net loss increased by approximately $52 million (45%) year-over-year, driven primarily by a $45.5 million increase in R&D expenses.
• R&D Drivers: R&D spending rose due to a $22.7 million increase in manufacturing costs (expanded cell processing and commercial readiness) and a $17.3 million increase in clinical trial costs (higher enrollment across multiple studies).
• Financing Activity: In June 2025, the company raised approximately $93.6 million in net proceeds through a public offering of common stock, pre-funded warrants, and warrants. Additionally, the company raised $10.2 million via its "at-the-market" (ATM) program during 2025.
• Manufacturing Expansion: The company entered into new manufacturing agreements with Lonza (December 2024) and Cellares (January 2026) to scale production, moving beyond its reliance on Minaris.

Guidance, Outlook, and Risks

Going Concern Warning: Management has identified conditions that raise substantial doubt about the company's ability to continue as a going concern for at least twelve months following the filing date. The company expects its current cash position to fund operations only into the fourth quarter of 2026.

Outlook & Milestones:

• Myositis: Registrational cohort initiated in December 2025; Biologics License Application (BLA) submission anticipated in 2027.
• SLE, SSc, gMG: Complete Phase 1/2 data expected in the first half of 2026. Registrational cohort designs for SLE and SSc expected to be announced in the first half of 2026.
• Manufacturing: Initial clinical experience with the automated Cellares Cell Shuttle platform expected in the first half of 2026.

Key Risks:

• Capital Requirements: Substantial additional financing is required to complete clinical trials and commercialize products. Failure to secure funding could force delays or discontinuation of programs.
• Regulatory Uncertainty: The company plans to use single-arm trial designs with external controls for registrational trials, which faces heightened FDA scrutiny regarding bias and data reliability.
• Manufacturing Dependence: Reliance on third-party CDMOs (Minaris, Lonza, Cellares) creates supply chain risks.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for the next capital raise given the "substantial doubt" going concern disclosure and the Q4 2026 funding horizon.
• Dilution Impact: Review the terms of the June 2025 offering and outstanding warrants (53 million warrants at $2.50 exercise price) to assess potential dilution.
• Regulatory Feedback: Monitor FDA communications regarding the acceptability of the external control registry data for the myositis registrational trial.
• Manufacturing Transition: Track the successful transfer of manufacturing processes to Lonza and Cellares to ensure supply continuity for registrational trials.
• License Obligations: Review milestone payment triggers under the IASO license agreement (up to $162 million total consideration) and potential future cash outflows.